Abstract
We report a patient with chronic lymphocytic leukemia (CLL) who developed idiopathic thrombocytopenic purpura (ITP) and myasthenia gravis (MG) after fludarabine therapy. ITP developed after 6 cycles of fludarabine treatment, and MG occurred 2 months after the onset of ITP. MG was successfully treated with immunosuppressive therapy and plasma exchange, while rituximab was effective for CLL and ITP. Fludarabine seemed to have an important role in the onset of ITP and MG in this case.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
-
Male
-
Middle Aged
-
Myasthenia Gravis / chemically induced*
-
Myasthenia Gravis / drug therapy
-
Myasthenia Gravis / immunology
-
Purpura, Thrombocytopenic, Idiopathic / chemically induced*
-
Purpura, Thrombocytopenic, Idiopathic / drug therapy
-
Purpura, Thrombocytopenic, Idiopathic / immunology
-
Rituximab
-
Salvage Therapy
-
Treatment Outcome
-
Vidarabine / adverse effects
-
Vidarabine / analogs & derivatives*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Rituximab
-
Vidarabine
-
fludarabine